Half Year Results 

Oxford Biomedica expects stronger second half

Oxford Biomedica expects stronger second half

In recent months, the name Oxford Biomedica (OXB) has been closely linked with the Oxford University/AstraZeneca Covid-19 vaccine trials. The gene- and cell-therapy specialist has signed a three-year master supply and development agreement with AstraZeneca for the large-scale manufacture of the potential inoculation, and the pharma giant has paid Oxford Biomedica an upfront £15m capacity reservation fee. If the vaccine programme continues, it could receive additional revenues of more than £35m through to the end of 2021.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now